Navigation Links
MatTek's EpiDerm In Vitro Tissues Headed for Validation in Europe
Date:10/8/2008

Acceptance Will Reduce Animal Use in Cosmetics and Chemicals Testing

ASHLAND, Mass., Oct. 8 /PRNewswire/ -- MatTek Corp. today announced that results of a recently completed US and European multi-laboratory "catch-up" validation study on MatTek's EpiDerm in vitro human skin tissue equivalent. The test results demonstrated the required sensitivity and specificity for EpiDerm to be accepted as a validated alternative to animal testing for determining human skin irritation by the European ECVAM Scientific Advisory Committee (ESAC).

Horst Spielmann, former Director, ZEBET (BfR), commenting on the skin irritation catch-up validation studies in AltTox.org, noted that the "take home message" from these new studies is that EpiDerm was not only successfully validated using just one endpoint (cytotoxicity -- MTT viability), but also that the EpiDerm classification test results met the criteria set by the validated skin irritation test method.

The results obtained for EpiDerm in the catch-up validation studies have been submitted to ECVAM for approval by the ECVAM Scientific Advisory Committee (ESAC) at its next meeting on Nov. 3-4, 2008.

Spielmann went on the say that it would be helpful in promoting the new in vitro skin irritation test in Europe if these catch-up validation results are taken into account at the OECD Expert Meeting being held in Berlin, Germany on October 20-21, 2008 to review the new Draft OECD Test Guideline on "In Vitro Skin Irritation: Human Skin Model." Inclusion of EpiDerm in this OECD Test Guideline will lead to EpiDerm acceptance in the very near future to meet the skin irritation testing requirements of the 6th amendment of the EU Cosmetics Directive and of the new EU Chemicals Directive (REACH).

John Sheasgreen, MatTek's President, added, "It is very gratifying to see MatTek's almost 15 years of in vitro human tissue equivalent development and production culminating in the full validation of these tissues as alternatives to animal testing."

About MatTek -- MatTek Corp., founded in 1985, is the world's largest independent producer of in vitro human epithelial tissue equivalents. With over 400 technical references supporting its of claim of "Unsurpassed Tissue Reproducibility," MatTek human tissue equivalents are used in product development, claims substantiation (over 100 company patents cite the use of MatTek tissues), safety assessment, and drug discovery/development in many industries including Cosmetics, Personal Care, Household Products, Chemicals, Pharmaceuticals and Biotech.


'/>"/>
SOURCE MatTek Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria
2. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
3. Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
4. Georgia Reproductive Specialists Participates in Largest-Ever In Vitro Fertilization Clinical Trial in the World
5. Newly Published Study Shows OPKOs siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
6. NewCardio Announces Positive Results From Third Clinical Validation Study
7. M. D. Anderson to Initiate Clinical Validation Study on Rosetta Genomics MicroRNA-based Diagnostic Assay Identifying the Origin of Cancer Metastases
8. Michael J. Fox Foundation Awards $2.4 Million for Validation of Nine Promising Therapeutic Targets for Parkinsons Disease
9. ACRIN Study Endorses Virtual Colonoscopy - Validation for Colon CAD Software Maker Medicsight plc
10. NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium
11. IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following September Meeting of European Committee for Medicinal Products for Human Use (CHMP)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 /PRNewswire/ ... Diabetes Tomorrow,s Leaders Scholarship is any indication, the future ... today online at www.diabetesscholars.org by the Diabetes ... stand in the way of academic and community service ... scholarship program since 2012, and continues to advocate for ...
(Date:6/23/2016)... June 23, 2016 The vast majority of ... dialysis facility.  Treatments are usually 3 times a week, ... visit, including travel time, equipment preparation and wait time. ... especially grueling for patients who are elderly and frail.  ... nursing and rehabilitation centers for some duration of time. ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced ... feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as a ... has released tools for healthy coping following a traumatic event. , Trauma sufferers tend ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg ... Legal Elite. The attorneys chosen by their peers for this recognition are considered among ... Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite Hall ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... People across ... in Genome magazine’s Code Talker Award, an essay contest in which patients and their ... award to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual ...
(Date:6/24/2016)... ... 24, 2016 , ... Strategic Capital Partners, LLC (SCP) in ... investment capital for emerging technology companies. SCP has delivered investment events and ... more than a million dollars of capital investment for five companies. ...
Breaking Medicine News(10 mins):